Literature DB >> 26942734

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

Kathleen E Corey1,2, Mary E Rinella3,4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in the USA with a growing prevalence worldwide. Nonalcoholic steatohepatitis (NASH), progressive form of NAFLD, can lead to the development of cirrhosis, hepatocellular carcinoma, and the need for liver transplantation. Treatment of NASH may decrease the risk of progressive disease. Treatment for NAFLD should center around weight loss and exercise. Pharmacotherapy with vitamin E and pioglitazone should be considered for those with NASH, especially those with fibrosis. Weight loss surgery is also an effective treatment for NASH in individuals with other indications for surgery. In this review, we will discuss the currently available therapies for NASH including lifestyle, pharmacologic, and surgical options.

Entities:  

Keywords:  Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Pioglitazone; Vitamin E; Weight loss surgery

Mesh:

Substances:

Year:  2016        PMID: 26942734      PMCID: PMC4838504          DOI: 10.1007/s10620-016-4083-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  79 in total

Review 1.  Statins and hepatotoxicity: focus on patients with fatty liver.

Authors:  Naga Chalasani
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

2.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Authors:  John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

Review 3.  Intermediary metabolism of fructose.

Authors:  P A Mayes
Journal:  Am J Clin Nutr       Date:  1993-11       Impact factor: 7.045

4.  Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism.

Authors:  Claudia O Zein; Rocio Lopez; Xiaoming Fu; John P Kirwan; Lisa M Yerian; Arthur J McCullough; Stanley L Hazen; Ariel E Feldstein
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

5.  Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome.

Authors:  Samer G Mattar; Laura M Velcu; Mordechai Rabinovitz; A J Demetris; A M Krasinskas; Emma Barinas-Mitchell; George M Eid; Ramesh Ramanathan; Debra S Taylor; Philip R Schauer
Journal:  Ann Surg       Date:  2005-10       Impact factor: 12.969

Review 6.  Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism.

Authors:  Peter J Havel
Journal:  Nutr Rev       Date:  2005-05       Impact factor: 7.110

7.  Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Authors:  Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

8.  Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.

Authors:  Edgar R Miller; Roberto Pastor-Barriuso; Darshan Dalal; Rudolph A Riemersma; Lawrence J Appel; Eliseo Guallar
Journal:  Ann Intern Med       Date:  2004-11-10       Impact factor: 25.391

9.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

10.  Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity.

Authors:  Alice P Liou; Melissa Paziuk; Jesus-Mario Luevano; Sriram Machineni; Peter J Turnbaugh; Lee M Kaplan
Journal:  Sci Transl Med       Date:  2013-03-27       Impact factor: 17.956

View more
  12 in total

Review 1.  Impact of etiological treatment on prognosis.

Authors:  Chien-Wei Su; Ying-Ying Yang; Han-Chieh Lin
Journal:  Hepatol Int       Date:  2017-07-12       Impact factor: 6.047

Review 2.  NASH: The Emerging Most Common Form of Chronic Liver Disease.

Authors:  Meron Tesfay; W Joseph Goldkamp; Brent A Neuschwander-Tetri
Journal:  Mo Med       Date:  2018 May-Jun

3.  Managing the Burden of Non-NASH NAFLD.

Authors:  Christopher J Danford; Jorge E Sanchez; Kathleen E Corey
Journal:  Curr Hepatol Rep       Date:  2017-10-27

Review 4.  Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus.

Authors:  Jordan E Lake; Turner Overton; Susanna Naggie; Mark Sulkowski; Rohit Loomba; David E Kleiner; Jennifer C Price; Kara W Chew; Raymond T Chung; Kathleen E Corey
Journal:  Clin Gastroenterol Hepatol       Date:  2020-10-16       Impact factor: 11.382

Review 5.  Non-alcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri
Journal:  BMC Med       Date:  2017-02-28       Impact factor: 8.775

Review 6.  A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH).

Authors:  Manca Povsic; Louisa Oliver; Neha Raju Jiandani; Richard Perry; Juliana Bottomley
Journal:  Pharmacol Res Perspect       Date:  2019-05-27

Review 7.  A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH).

Authors:  Manca Povsic; On Yee Wong; Richard Perry; Juliana Bottomley
Journal:  Adv Ther       Date:  2019-05-07       Impact factor: 3.845

8.  The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study.

Authors:  Maria-Magdalena Balp; Nancy Krieger; Raymond Przybysz; Nate Way; Jennifer Cai; Dion Zappe; Sarah Jane McKenna; Garth Wall; Nico Janssens; Elliot Tapper
Journal:  JHEP Rep       Date:  2019-06-15

Review 9.  Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach.

Authors:  Ivica Grgurevic; Kristian Podrug; Ivana Mikolasevic; Michal Kukla; Anita Madir; Emmanuel A Tsochatzis
Journal:  Can J Gastroenterol Hepatol       Date:  2020-01-21

10.  Non-alcoholic fatty liver and the gut microbiota.

Authors:  Stavros Bashiardes; Hagit Shapiro; Shachar Rozin; Oren Shibolet; Eran Elinav
Journal:  Mol Metab       Date:  2016-06-14       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.